Ceruletide in Pancreatic Function Research: Advanced Protoco
2026-08-06
Ceruletide (Caerulein) is the gold-standard tool for modeling pancreatic fibrosis and gastrointestinal physiology, enabling reproducible, high-impact studies. This article translates recent mechanistic advances and practical troubleshooting tips into actionable workflows for digestive disorder research teams.
NS1-Driven DNMT1 Degradation Controls HBoV1 Replication and
2026-08-06
This study uncovers how human bocavirus 1 (HBoV1) exploits host DNA methylation pathways for its replication, with the viral NS1 protein targeting DNMT1 for proteasomal degradation. The findings establish a dual regulatory role for DNMT1 in promoting viral DNA synthesis while repressing RNA processing, offering new insight into epigenetic control points relevant to antiviral research.
Acetylcysteine in 3D Tumor Microenvironment Modeling
2026-08-05
Explore how Acetylcysteine (N-acetyl-L-cysteine) advances 3D tumor microenvironment models by modulating oxidative stress pathways and chemoresistance. Gain a unique systems-level perspective on assay design and translational research opportunities.
Tofacitinib (CP-690550): Redefining Immune Metabolic Modulat
2026-08-05
Explore how Tofacitinib (CP-690550) uniquely bridges immune modulation and cellular metabolism—delivering advanced insight into cytokine signaling blockade and mitochondrial repair research. This article offers expert analysis distinct from existing content.
SGC-CBP30: Selective CREBBP/EP300 Bromodomain Inhibitor Insi
2026-08-04
SGC-CBP30 is a potent, selective CREBBP/EP300 bromodomain inhibitor validated for epigenetics research and cancer biology. Robust evidence demonstrates its utility in dissecting transcriptional coactivator functions, particularly in early-stage lung adenocarcinoma models. This article clarifies SGC-CBP30’s mechanism, application limits, and integration into advanced workflows.
3-Aminobenzamide (PARP-IN-1): Applied Workflows for PARP Inh
2026-08-04
3-Aminobenzamide (PARP-IN-1) enables precise and reproducible poly (ADP-ribose) polymerase inhibition across cardiovascular, metabolic, and host-pathogen research models. This article delivers protocol-driven insights, troubleshooting strategies, and translational perspectives, highlighting how APExBIO’s formulation stands out for both reliability and experimental versatility.
Sex Differences in Angiotensin II-Induced Hypertension in Mi
2026-08-03
Xue et al. provide the first direct evidence that male and female mice display markedly different hypertensive responses to chronic angiotensin II (ANG II) infusion. Their findings clarify how sex hormones and autonomic regulation shape these outcomes, emphasizing the importance of considering sex as a biological variable in hypertension and cardiovascular research.
CIP2A Promotes PKM2 Tetramerization and OXPHOS in NSCLC Meta
2026-08-03
This study demonstrates that CIP2A, an oncogenic regulator, promotes oxidative phosphorylation in non-small cell lung cancer by inducing PKM2 tetramerization and mitochondrial localization. These findings challenge the traditional Warburg-centric view of cancer metabolism and suggest new therapeutic strategies targeting CIP2A and glycolysis in NSCLC.
M1 Macrophage Exosomes Drive Enteric Neuronal Injury via MMP
2026-08-02
This study uncovers a critical neuroimmune mechanism in which M1 macrophage-derived exosomes enriched in MMP8 induce enteric neuronal apoptosis through TGF-β pathway activation, contributing to gastrointestinal motility disorders. The findings highlight MMP8 as a potential therapeutic target and provide mechanistic insights relevant for researchers studying neuroimmune regulation of gut motility.
Boc-D-FMK: Pan-Caspase Inhibitor for Apoptosis & Inflammatio
2026-08-01
Boc-D-FMK is a cell-permeable, irreversible pan-caspase inhibitor used to block apoptotic and inflammatory signaling in vitro and in vivo. Its robust inhibition of caspase activity and downstream TNF-α pathways makes it a standard tool in apoptosis research. Evidence-based protocols ensure reproducible outcomes in renal endothelial and hepatocyte apoptosis models.
Belinostat (PXD101): Protocol-Driven Advances in Cancer Rese
2026-07-31
Belinostat (PXD101) stands out as a potent pan-HDAC inhibitor, enabling precise epigenetic modulation in in vitro cancer models. This article delivers actionable protocols, troubleshooting strategies, and evidence-backed workflow enhancements to maximize assay reproducibility and insight, especially in bladder and prostate cancer research.
TREM2 Controls Microglial Activation via ERK/p38 in Autoimmu
2026-07-31
This study identifies TREM2 as a regulator of microglial activation and inflammation in experimental autoimmune uveitis by modulating the ERK/p38 MAPK pathway. The findings offer mechanistic insight into retinal immune responses and highlight TREM2 as a potential therapeutic target for non-infectious uveitis.
Dovitinib (TKI-258): Targeting Tumor Hypoxia and Immunometab
2026-07-30
Explore how Dovitinib (TKI-258) reshapes cancer research by intersecting RTK inhibition with hypoxia-driven immunometabolic pathways. This in-depth analysis delivers unique insights into experimental design, apoptosis induction in cancer cells, and the evolving landscape of tumor-targeted therapies.
Applied Use of CNQX for Targeted Glutamatergic Inhibition
2026-07-30
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) enables precise blockade of AMPA and kainate receptors, making it an indispensable tool for dissecting non-NMDA glutamatergic signaling in central nervous system research. This guide distills advanced experimental workflows, real-world troubleshooting, and application-driven insights grounded in recent cardiovascular-neuroscience breakthroughs.
Applied Workflows for Amyloid Beta-peptide (25-35) Neurotoxi
2026-07-29
Amyloid Beta-peptide (25-35) (Aβ25-35) is the gold standard for modeling Alzheimer’s neurotoxicity, enabling precise dissection of microglial activation and amyloid-induced cell death. This guide reveals optimized workflows, troubleshooting strategies, and translational insights, leveraging APExBIO’s rigorously validated peptide for reproducible, high-impact research.
470 records 10/32 page Previous Next First page 上5页 678910 下5页 Last page